文献速递肺栓塞与肺血管病间质性肺疾病

间质性肺疾病相关肺动脉高压治疗进展

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

纤维化间质性肺疾病患者常并发肺动脉高压,显著增加疾病负担与死亡风险。既往将肺动脉高压靶向药物超适应证用于此类患者,疗效证据矛盾;近期最大规模研究显示获益,促成美国首个获批疗法。本文综述既往研究困境、管理流程及未来试验方向。

要点

  • 纤维化间质性肺疾病相关肺动脉高压与发病率及死亡率显著增加相关。
  • 肺动脉高压靶向药物超适应证用于间质性肺疾病患者,既往研究疗效证据矛盾。
  • 近期最大规模研究显示获益,促成美国首个获批疗法。

核心结论

  • 间质性肺疾病相关肺动脉高压治疗领域近期出现范式转变,最大规模研究显示获益并促成美国首个获批疗法。

研究设计与样本

  • 本文为简明临床综述,概述既往研究及药物开发面临的问题,并提供实用管理流程与未来临床试验考量。

主要发现

  • 肺动脉高压常并发于纤维化间质性肺疾病病程,与发病率及死亡率显著增加相关。
  • 肺动脉高压靶向药物因肺动脉高压适应症获批而被超适应证用于间质性肺疾病患者。
  • 间质性肺疾病相关肺动脉高压是适应性反应还是可治疗的适应不良现象,既往不确定。
  • 既往部分研究提示治疗获益,另有研究显示 harm。
  • 近期最大规模研究显示获益,促成美国首个获批疗法。

临床怎么用

  • 在定义变化、共病因素及已有治疗选择的背景下,可采用本文提供的实用管理流程。

局限性

  • 既往药物开发因研究结果矛盾而受阻,该患者群体亟需治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension, frequently complicating the course of patients with fibrotic interstitial lung disease, is associated with significantly increased morbidity and mortality. The availability of multiple medications to treat pulmonary arterial hypertension has resulted in these agents being used beyond their original indication, including in patients with interstitial lung disease. Whether pulmonary hypertension in the context of interstitial lung disease is an adaptive response not to be treated or a maladaptive phenomenon amenable to therapy has been uncertain. Although some studies have suggested a benefit of treatment, there have been others demonstrating harm. This concise clinical review provides an overview of prior studies and the issues that have plagued drug development for a patient population in dire need of treatment options. More recently, there has been a paradigm shift, with the largest study to date demonstrating benefit, resulting in the first approved therapy in the United States for patients with interstitial lung disease complicated by pulmonary hypertension. A pragmatic management algorithm in the context of changing definitions, comorbid contributors, and an available treatment option is provided, as are considerations for future clinical trials.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Nathan SD. Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Am J Respir Crit Care Med. 2023. PMID: 37159942. doi:10.1164/rccm.202212-2342CI

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。